Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 49.5x - 54.7x | 52.1x |
| Selected Fwd P/E Multiple | 9.8x - 10.8x | 10.3x |
| Fair Value | €17.42 - €19.25 | €18.34 |
| Upside | -0.5% - 10.0% | 4.8% |
| Benchmarks | - | Full Ticker |
| Aquestive Therapeutics, Inc. | - | NasdaqGM:AQST |
| Amneal Pharmaceuticals, Inc. | - | NasdaqGS:AMRX |
| Teva Pharmaceutical Industries Limited | - | OTCPK:TEVJ.F |
| Pfizer Inc. | - | NYSE:PFE |
| Merck & Co., Inc. | - | NYSE:MRK |
| Indivior PLC | - | DB:2IVB |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| AQST | AMRX | TEVJ.F | PFE | MRK | 2IVB | |||
| NasdaqGM:AQST | NasdaqGS:AMRX | OTCPK:TEVJ.F | NYSE:PFE | NYSE:MRK | DB:2IVB | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | -5.6% | 24.6% | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | -29.0% | 11.5% | NM- | ||
| Latest Twelve Months | -152.9% | 101.9% | 65.3% | 513.7% | 19.4% | 145.3% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -96.5% | -2.9% | -10.6% | 19.4% | 19.2% | 1.6% | ||
| Prior Fiscal Year | -15.6% | -3.5% | -3.5% | 3.6% | 0.6% | 0.2% | ||
| Latest Fiscal Year | -76.7% | -4.2% | -9.9% | 12.6% | 26.7% | -4.0% | ||
| Latest Twelve Months | -147.4% | 0.1% | -0.9% | 16.8% | 25.8% | 4.5% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -8.9x | 8.9x | 8.1x | 7.9x | 8.7x | 8.6x | ||
| Price / LTM Sales | 10.9x | 1.1x | 1.3x | 2.3x | 3.4x | 2.6x | ||
| LTM P/E Ratio | -7.4x | 892.5x | -134.9x | 13.7x | 13.3x | 57.3x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -134.9x | 13.3x | 892.5x | |||||
| Historical LTM P/E Ratio | -8.9x | 15.5x | 70.6x | |||||
| Selected P/E Multiple | 49.5x | 52.1x | 54.7x | |||||
| (x) LTM Net Income | 53 | 53 | 53 | |||||
| (=) Equity Value | 2,621 | 2,759 | 2,897 | |||||
| (/) Shares Outstanding | 124.8 | 124.8 | 124.8 | |||||
| Implied Value Range | 21.01 | 22.11 | 23.22 | |||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | ||||
| Implied Value Range (Trading Cur) | 17.92 | 18.87 | 19.81 | 17.50 | ||||
| Upside / (Downside) | 2.4% | 7.8% | 13.2% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | AQST | AMRX | TEVJ.F | PFE | MRK | 2IVB | |
| Value of Common Equity | 481 | 3,012 | 16,427 | 147,142 | 218,231 | 2,559 | |
| (/) Shares Outstanding | 121.0 | 314.1 | 1,147.2 | 5,685.6 | 2,497.8 | 124.8 | |
| Implied Stock Price | 3.98 | 9.59 | 14.32 | 25.88 | 87.37 | 20.51 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |
| Implied Stock Price (Trading Cur) | 3.98 | 9.59 | 14.32 | 25.88 | 87.37 | 17.50 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |